The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such as continuous glucose monitors, insulin pumps and automated insulin dosing systems that rely on a smartphone for delivering alerts. The agency said it received medical device reports in which users reported alerts were not being delivered or heard in situations where the users thought they configured the alerts to be delivered. Some instances may have contributed to serious harm, including severe hypoglycemia, severe hyperglycemia, diabetic ketoacidosis and death.   

The FDA issued recommendations for users and said it is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations are evaluated prior to use. It is also working with manufacturers to ensure settings for smartphones and mobile medical applications are continuously tested and that updates are communicated quickly and clearly to users.

Related News Articles

Headline
The White House Dec. 11 issued an executive order to establish a national artificial intelligence framework to preempt state regulation. The order calls for…
Headline
The Cybersecurity and Infrastructure Security Agency Dec. 11 released an update to its voluntary Cybersecurity Performance Goals, which includes measurable…
Headline
U.S. and international agencies are warning of potential cyberattacks on health care and other critical infrastructure from state-sponsored cyber actors in…
Headline
John Pastor, president of Fairview Pharmacy Services and chief operating officer of Fairview Pharmacy Solutions, shares how M Health Fairview’s expansive…
Headline
U.S. and international agencies Dec. 3 released guidance on integrating artificial intelligence into operational technology. The guidance is intended to…
Headline
A critical, unauthenticated remote code execution vulnerability known as React2Shell has been added to the Cybersecurity and Infrastructure Security Agency’s…